ProText Mobility Inc (TXTM)

[La Dolce Vita]

"We will also be using a portion of the proceeds to fund the research and development of Protext Pharma, who will be finishing the development of a full-profile medical cannabis extract for pharmaceutical applications. This extract is expected to include the acid-form precursor cannabinoids THC-A and THC-B together with the CBD precursors in a non-psychoactive complex. Pending approval to commence operations from the South African government, this medical cannabis production should commence in the first part of 2018.”